Syngene International Ltd. · NSE:SYNGENE
Syngene International — Investor Presentation (October 2022)
39 slides from Syngene International's investor presentation, Oct 19, 2022
Slide 1: Exchange filing cover letter for Investor Presentation
Ref: Syn/CS/SE/IP/2022-23/Oct/07 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com October 19, 2022 T
Slide 2: Investor Presentation October 2022
Investor Presentation October 2022
Slide 3: Safe harbour
Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 4: Contents
Contents 1 Operating Highlights 2 Syngene – Putting Science to Work 3 Syngene strengths 4 Financials 5 Shareholding and Share Information Appendix Putting Science to Work 3
Slide 5: Operating Highlights
Aly Operating Highlights Syngene
Slide 6: Q2 FY23 performance
Q2 FY23 performance Operating Highlights Q2 Financial Highlights • Positive performance across all divisions The second quarter results are against a strong quarter last year due to sale of remdesivir. Underlying performance, excluding the impact of remdesivir in the • Sustained growth in research d
Slide 7: FY23 guidance: upgraded revenue growth guidance of high teens maintained
FY23 guidance: upgraded revenue growth guidance of high teens maintained Parameter FY23 Guidance (April 2022) Revised FY23 Guidance (July 2022) FY23 Guidance (October 22) Revenue from Mid-teen growth High- teen growth High- teen growth operations EBITDA Margin EBITDA margin around 30%. EBITDA margin
Slide 8: Syngene – Putting Science to Work
2 Syngene – Putting Science to Work
Slide 9: Partner in innovation: #Puttingsciencetowork
Partner in innovation: #Puttingsciencetowork Who we are and what we do We aim to be a world class partner delivering innovative scientific solutions for clients We offer integrated Sector expertise includes: Our team includes ~6000 Established track record in solutions across pharmaceuticals, biotec
Slide 10: Key facts and figures
Key facts and figures 400+ 15 400+ World class active clients collaborations Patents infrastructure with top 20 pharmaceutical held with clients of 2 Mn sq. ft. qualified to companies meet international standards Rs. 39,435 Mn Rs. 26,570 Mn Rs. 4,211 Mn 5,200+ (US$526Mn*) (US$354Mn*) (US$56Mn*) Tale
Slide 11: International accreditations
International accreditations • USFDA,OHSAS 18001, • GLP, cGMP, AAALAC & CPCSEA Certified facilities • CAP accreditation, ISO/IEC 27001:2013 accreditation • EMA and PMDA approved, AAALAC accredited facility • The safety assessment laboratories and large molecule bioanalytical lab are ISO IEC 17025:20
Slide 12: Experience across multiple industry segments and global partnerships
Our experience spans multiple industry segments and partnerships with global leaders across the world Large & Emerging Animal Consumer mid-sized Universities Agrochem biopharma health products biopharma Putting Science to Work 11
Slide 13: Our journey so far
Our journey so far 2019 – 2022 Continued investments and Globalization and strategic collaboration • Expanded into formulations development growth • Contract with Endo Pharmaceuticals to develop novel anti cancer • Expanded collaboration with BMS, biological therapeutic molecules Amgen and Zoetis •
Slide 14: Broad capabilities spanning the value chain
Our broad capabilities, spanning the value chain, facilitates integration and captures additional benefits for clients Research business Development and Manufacturing business Discovery Services Dedicated R&D Centers Development Services Manufacturing Services Flexible Platform with capability Ring-
Slide 15: A 'one-stop-shop' for discovery research, development and manufacturing services
A 'one-stop-shop' for discovery research, development and manufacturing services (small and large molecules) Discovery Development Manufacturing Small Drug Substance Chemistry Molecules Large Development Clinical Supplies Molecules Drug Product Development Biology Integrated Drug Substance – Drug Pr
Slide 16: Flexible collaboration models
Flexible collaboration models 1 2 3 4 5 6 Dedicated R&D centers Full time equivalent (FTE) Fee for service Productivity-based model Risk-reward Delivery-based contract for CDMO business • Dedicated scientific • Pre-defined numbers • Client contracts for • Resources and services • Relationship spans
Slide 17: Our state-of-the-art infrastructure
Our state-of-the-art infrastructure Bangalore campus 90 acres housing most of Syngene’s capabilities Discovery Services Hyderabad campus commenced operation in Aug 2019 API Manufacturing Mangalore campus Biologics Commissioned March 2020 Bangalore campus Reactor size: 2-12KL Manufacturing plant scal
Slide 18: Experienced workforce: building capabilities and careers
Experienced workforce: building capabilities and careers ~6000 Inspiring technical excellence and providing opportunities to grow strong total headcount Nurturing young • Syngene Training Academy offers new graduate recruits a six-month extended induction to help them 5,200+ scientists talent and en
Slide 19: Operational robustness driving strategy execution
Operational robustness driving strategy execution Continuous improvement embedded in operations Expansion of infrastructure and technological driven by certified operational leaders capabilities to support future growth Six Sigma Black Belt certified staff in each service line and Building with redu
Slide 20: Syngene strengths
3 Syngene strengths Syngene
Slide 21: Syngene strengths
Syngene strengths A global scale CRO/CDMO Solutions through innovation Quality matters • Integrated Drug Discovery, Development and • IP fully assigned to clients • Fully digitized quality organization Manufacturing service provider • Track record of data management and • Strong compliance track rec
Slide 22: Strong track record of growth and profitability
Strong track record of growth and profitability Total Revenue (Rs. Mn) EBITDA (Rs. Mn) Profit Before Tax * (Rs. Mn) FY18 to FY22 - CAGR 16% FY18 to FY22 - CAGR 13% FY18to FY18 toFY22 FY22--CAGR CAGR8% 8% 8,489 26,570 7,364 5,151 6,995 22,489 6,119 4,456 4,342 20,935 4,154 19,007 5,266 3,725 14,849 F
Slide 23: Levers for future growth
Levers for future growth Expand/extend existing clients Capacity expansion • Service integration • Continuous investment • Flexible business models including • FTE services, manufacturing, formulation, dedicated centers biologics, stability Engage New Clients • Tailored service offerings, high quali
Slide 24: Committed to safety and sustainability
Committed to safety and sustainability Safety is our first priority Committed to environmental protection • Accredited with ISO 45001:2018 for Occupational Health and Safety • Accredited with ISO 14001:2015 for our Environment Management System (OH&S) measures • 20% reduction in freshwater usage; 15
Slide 25: Industry recognition for our scientific capability and best practices
Industry recognition for our scientific capability and best practices • Bio-Excellence Award 2018: At Bengaluru • CMO Leadership Award Winner 2020 - under • CMO Leadership Awards 2022 Received 6 awards for all Tech Summit, Bengaluru Categories: Capabilities, Compatibility, categories, including Capa
Slide 26: Robust risk management framework
Robust risk management framework Syngene has a risk management framework to identify, monitor, report and manage risk. Every risk owner monitors and manages risks relevant to their area of responsibility. Executive Committee (EC) Board of Directors(BOD) • Sign off on Enterprise Risk Framework annual
Slide 27: Financials
4 Financials
Slide 28: Q2FY23 financial highlights
Q2FY23 financial highlights Particulars Q2 FY23 Q2 FY22 YoY Change Q1 FY23 QoQ change Revenue from Operations 7,681 6,102 26% 6,445 19% Other Income 154 129 20% 155 0% Total Revenue 7,835 6,231 26% 6,600 19% Material costs 1,990 1,675 19% 1,612 23% Staff cost 2,185 1,892 15% 1,971 11% Other direct c
Slide 29: H1FY23 financial highlights
H1FY23 financial highlights Particulars H1 FY23 H1 FY22 YoY Change Revenue from Operations 14,126 12,047 17% Other Income 309 252 23% Total Revenue 14,435 12,299 17% Material costs 3,602 3,621 -1% Staff cost 4,156 3,656 14% Other direct costs 571 387 48% Other Expenses 1,684 1217 38% Foreign exchang
Slide 30: FY22 financial highlights
FY22 financial highlights Particulars FY22 FY21 YoY Change Balance Sheet Highlights Revenue from operations (excl export incentives) 26,042 21,843 19% Other Income 528 646 (18%) Total Revenue 26,570 22,489 18% As on 31st March 2022 Material and power costs 8,138 5,839 39% Employee costs 7,181 6,602
Slide 31: Shareholding and Share Information
Shareholding and Share 5 Information
Slide 32: Syngene and Biocon Group
Syngene and Biocon Group Syngene is an operationally independent publicly listed Biocon Limited, founded in 1978, is an innovation-led global subsidiary of Biocon Limited, established in 1993 as India’s biopharmaceuticals company and has majority holding in key first Contract Research Organization.
Slide 33: Shareholding and Share Information
Shareholding and Share Information Syngene’s Shareholding Pattern* Syngene’s Share Information* 0.5% NSE Ticker SYNGENE BSE Ticker 539268 Promoter & Market Cap (Rs. Mn) 2,25,205 34.6% Promoter Group Public % free-float 35% ESOP Trust Free-float market cap (Rs. Mn) 78,031 64.9% Share Outstanding (Mn)
Slide 34: For more details
For more details Visit our website www.syngeneintl.com https://twitter.com/SyngeneIntl https://www.linkedin.com/company/syngene-international-limited https://www.facebook.com/syngeneintl/ https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ IR Contact: Media Contact: Krishnan G Shotorupa Ghosh +
Slide 35: Appendix
J Appendix Syngene
Slide 36: Discovery Services
Discovery Services Target Identification and Hit HitHit to Lead to Lead Optimization Lead IND Enabling IND IND IND / Ph1 / DE Validation Identification Lead Optimization Enabling Ph1 DE Target ID In vitro assays: In In vitro vitro assays: assays: In Invivo vivoassays/studies: assays/studies: Later T
Slide 37: Development Services and Manufacturing Services
Development Services and Manufacturing Services Developability Development Clinical Phase Registration/process Commercial Assessment phase Phase I Phase II Phase III validation batches Early PK, MTD/DRF studies, • IND enabling GLP Tox studies: Ames, Chromosomal • NDA enabling studies: Sub- chronic a
Slide 38: Biologics Development and Manufacturing services
Biologics Development and Manufacturing services Developability Development Clinical Phase Registration/process Commercial Assessment phase Phase I Phase II Phase III validation batches • Cell line development / • Clone to GMP • Process DOE, robustness and safety study selection • Upstream process O
Slide 39: Thank you
Thank you © 2022 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the
Syngene International — Investor Presentation (October 2022) on 6ix